Despite advancements in neuroscience over the past 60 years, unmet need persists for people living with disorders of the nervous system with neurological conditions being the third most common cause of disability and premature death in Europe. However, there has been significant progress in understanding and treating these diseases. At Janssen, we never stop pushing the boundaries of what is possible to the benefit of the patients.
At Janssen, we are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders.
Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
Nervous system disorders are more common than you think
Central nervous system disorders are the second leading cause of death worldwide, and it is estimated that one third of people living in Europe will be affected by a neurological disorder in their lifetime.
We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.
Holding patients and caregivers at our core
Our ultimate responsibility remains to our patients who, alongside caregivers, are at the heart of everthing we do.
We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors. It is essential to work in partnership with the patient community to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.
This is why we work with around 30 patient and carer organisations across Europe to enhance our understanding of living with nervous system diseases. We are part of a broadly-based healthcare company, with a decentralised structure which assures that we remain focused on the markets in every therapeutic and geographical area that we serve.
Leading the way through innovation
Our medications and innovations have helped improve the quality of care for millions of people living with neuropsychiatric conditions.
Today, we are committed to maintaining innovative Research and Development (R&D) that solves for unmet needs across nervous system disorders.
We are immensely proud of the many ground-breaking therapies Janssen has pioneered over the course of our 60+ year legacy in Neuroscience. At Janssen, the focus is on pushing the boundaries of what’s possible, evolving our work and knowledge to include neurological and autoantibody-driven diseases.
Janssen’s regional innovation teams operate out of four Innovation Centers in life science hubs, and incubation and acceleration with JLABS is available through 13 locations across the globe and virtually. Our Neuroscience team is also pioneering holistic “predict and pre-empt” paradigms that involve early diagnostics and patient management programmes.
Our global presence and cross-business portfolio provide us with the flexibility to build strong relationships and become the partner of choice for many collaborative opportunities in both established and emerging markets. In emerging markets, our vision is to enable the delivery of quality medicines, harness growth and expand businesses.
Our alliances take many forms, but our goal is always the same: to advance scientific research and deliver solutions that provide value to patients, physicians and society. We actively pursue new ways of collaborating in our core areas of interest and seek out like-minded health and technology companies to partner with.
We are expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation.LEARN MORE
We are utilising biomarker sciences to drive disease understanding, patient identification and accelerated development.Learn more
Neurological & Neuromuscular Disorders
We are leveraging shared pathology across diseases to broaden therapeutic opportunities.
Additional support for Alzheimer’s disease, major depressive disorder and schizophrenia can be accessed via the JanssenWithMe Mental Health support webpages.
“Our extensive research and innovations aim to improve the quality of care for millions of people with neurological conditions. We’ve equipped ourselves with the knowledge, tools and technology to expand our focus into the full range of psychosis spectrum disorders and mood dysregulation, and by leveraging shared pathology across disease areas to broaden therapeutic opportunities and develop innovations for populations with high unmet needs - such as, for instance in neurodegenerative and neurological disorders. We’re motivated by making a real difference for not just patients, but for society as a whole.”
Dr. Tamara Werner-Kiechle
EMEA Therapeutic Area Lead, Central Nervous System & Pulmonary Hypertension
Approximately 40 million people across the EU are living with depression and it is the leading cause of disability and disease burden worldwide. In an area of high unmet need our medications and innovations have helped improve the quality of care for millions of people living with neuropsychiatric disorders. However, there is a lot more work to be done.
Achieving response and remission with treatment in major depressive disorder (MDD) requires time and effort, which in turn prolongs patient suffering. Access to innovative treatments for neuropsychiatric disorders remains the best way to address suboptimal outcomes for patients.
We’re committed to using emerging science to develop novel therapies for the treatment of severe mood disorders, and are expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation.
Breaking Depression aims to raise awareness of the challenges of living with different types of depression, including MDD, and provides practical tools to help everyone start the right conversations with their loved ones and healthcare professionals to get the right support. The campaign has been started by Janssen, with support from the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Federation of Associations of Families of People with Mental Illness (EUFAMI).
By broadening our understanding of the different types of depression, we can all work together to help break depression for good.Pledge your support
The Little Book of Big Conversations
Developed in partnership with GAMIAN-Europe and EUFAMI, The Little Book of Big Conversations is a digital book containing practical advice to help people start conversations about depression.
Open and honest conversations about depression are an important step towards ensuring that people get the support they need. However, we understand that starting these conversations can be daunting and knowing where to begin can be difficult.Open the book
Plan Your Way Out of Depression
Everyone’s route out of depression is different, however the journey can be more difficult if made alone. Seeking help and finding ways to cope with depression can be helpful in a person’s journey out of depression.
Whatever route taken, supportive conversations with a doctor or another healthcare professional are often crucial. This is why we have partnered with GAMIAN-Europe and EUFAMI to create a free guide with practical tips to support people living with depression, and their caregivers, in getting the most out of each step in their journey but most importantly persevering towards recovery.Open your guide
We are in the midst of a scientific renaissance in neurodegeneration, driven by growing evidence of overarching biological processes that drive neurodegenerative disorders.
Our ambition at Janssen is to become a leader in neurodegeneration. We are working to develop innovations for a diverse range of patients, from large, clinically diverse populations. This work begins with research and development, where we have potentially transformational early science in Alzheimer’s disease and Parkinson’s disease.
Neurological & Neuromuscular Disorders
As part of our strategy to broaden our focus beyond neuropsychiatry, we acquired Momenta Pharmaceuticals and gained full rights to an anti-neonatal Fc receptor monoclonal antibody that has the potential to address a range of serious autoantibody-mediated autoimmune diseases, including certain neurologic and neuromuscular disorders. Significant unmet treatment needs remain in these disease areas, despite standard of care treatment options available.
We are committed to deepening our research in neurologic and neuromuscular conditions to help address the significant unmet need for therapies and treatments for patients. This acquisition also enhanced our pathway-based research and development approach across therapeutic areas.